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To determine the effect of thrombolytic therapy 
and/or immediate coronary angioplasty (PTCA) 
on left ventricularfunction. 129 patients with acute 
transmural myocardial infarction were retrospec- 
tively studied. Treatment strategies included 
thrombolytic therapy alone (n = 29), PTCA alone 
(n = 41), and combined thrombolytic therapy and 
PTCA (n = 59). Left ventricular ejection fraction 
(LVEF) and infarct zone regional wall motion 
(R WM) were determined from contrast ventricu- 
lography obtained acutely and at day 7-10. In the 
overall group, there was a 2 & 9% increase in 
LVEF (p < 0.02) and a 0.7 f 1.2 SD/chord in- 
crease in R WM (p < 0.0001) between day 1 and 
day 7-10. Patients with a patent infarct vessel at 
day 7-10 had a more significant change (A) in 
LVEF (3 f 8 vs -5 & 996, p = 0.0002) and 
RWM (0.8 f 1.2 vs 0.1 A 1.0 SD/chord, p 
< 0.02) than patients with .an occluded vessel. Pa- 
tients with a residual stenosis < 70% at day 7-10 
manifested a greater M V E F  (3 f 8 vs -5 f 9%. p 
< 0.01) and ARWW (0.9 k 1.2 vs 0.1 1.0 SD/ 
chord, p < 0.05) than patients who were occluded. 
There was a negative correlation between residual 
Introduction 
Preservation of left venticular function is a 
major determinant of survival following myocar- 
dial infar~ti0n.I~ With experimental demonstra- 
tion that restoration of blood flow after coronary 
occulsion reduces infarct size and improves re- 
gional thrombolytic therapy and per- 
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stenosis and AR WM (p < 0.04). Patients treated 
< 3 hours after symptom onset demonstrated a 
more significant AR WM when compared to pa- 
tients treated 23 hours (1.0 f 1.3 vs 0.5 f 1.1 
SD/chord, p .c 0.04). Patients treated with com- 
bined thrombolytic therapy and PTCA were ob- 
served to have a greater AR WM than patients 
treated with thrombolytic therapy alone (0.8 f 1.2 
vs 0.2 f 0.9 SD/chord, p < 0.05). Patients with an 
LVEF > 40% demonstrated a more significant 
M V E F  than patients 2 40% (7 k 8 vs I f 8%, p 
< 0.007). A signifcant improvement in ALVEF 
was noted only in patients with an anterior infarc- 
tion when compared to patients with an infirior 
infarction. Age, sex, presence of multivessel dis- 
ease, history ofprior myocardial infarction, initial 
patency of the infarct vessel, and presence of collat- 
erals had no effect on left ventricular function. 
Stepwise multiple regression identified residual 
stenosis, time to treatment, and the degree of ini- 
tial global impairment as the major joint predic- 
tors of ventricular functional recovev. (J Interven 
Cardiol 1988: 1:3) 
cutaneous transluminal coronary angioplasty 
(PTCA) have found increasing application in pa- 
tients with acute infar~tion.~-'O Although previous 
studies have evaluated the efficacy of these treat- 
ment strategies in promoting functional recovery, 
their results have 
This study was undertaken to assess the impact 
of thrombolytic therapy and/or immediate PTCA 
on left vetricular function during acute myocardial 
infarction and to determine variables which affect 
functional recovery. 
Methods 
Patient Selection. This report is a retrospective 
analysis of 184 consecutive patients with acute 
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transmural myocardial infarction who were in- 
volved in various reperfusion therapy protocols at 
the University of Michigan Medical Center be- 
tween January 1984 and February 1986. All pa- 
tients underwent emergent cardiac catheterization 
within 7 hours of symptom onset. 
In order to assess left ventricular function, only 
patients who underwent catheterization acutely 
and on repeat study at day 7-10 were studied. Of 
the 184 patients, 129 were included in the final 
analysis. Fifty-five were excluded because of tech- 
nically inadequate ventriculograms (n = 44) or an 
inability to obtain repeat catheterization (n = 11). 
Based upon clinical characteristics, there was no 
selection bias between the included and excluded 
groups. Twenty-nine patients were treated with 
thrombolytic therapy alone [recombinant tissue 
plasminogen activator (rt-PA)], 4 1 patients with 
immediate PTCA alone, and 59 patients with 
combined thrombolytic therapy [rt-PA (n = 34) or 
streptokinase (n = 25)] and immediate PTCA. In- 
formed consent was obtained prior to catheteriza- 
tion. 
Thrombolytic Therapy. Thrombolytic therapy 
was administered to 88 patients prior to catheter- 
ization. Twenty-five patients were treated with 
streptokinase and 63 with rt-PA. The dose of 
streptokinase was 1.5 million U intravenously 
over 30 minutes. The dose of rt-PA was 1.25 
mg/kg intravenously over 3 hours (n = 29) or 150 
mg over 6 hours (n = 34). The clinical exclusion 
criteria for thrombolytic therapy included (1) re- 
cent surgery, trauma, or cardiopulmonary resusci- 
tation; (2) previous cerebrovascular accident; (3) 
active bleeding; (4) bleeding diathesis; (5) malig- 
nant hypertension; (6) age > 75 years; and (7) car- 
diogenic shock. 
Catheterization Technique. All 129 patients un- 
derwent immediate catheterization upon arrival at 
the University of Michigan Medical Center. Fol- 
lowing vascular sheath insertion, heparin 5000 U 
was administered intravenously. Selective coro- 
nary arteriography was performed in multiple pro- 
jections. Contrast left ventriculography was per- 
formed in the 30” right anterior oblique position 
using a power injection of contrast through a pig- 
tail catheter. After catheterization, patients re- 
ceived heparin in a continuous intravenous infu- 
sion for 7- 10 days to maintain the activated partial 
thromboplastin time at 2 to 2.5 times control. In 
addition, aspirin 325 mg per day, dipryidamole 75 
mg three times per day, and diltiazem 30 - 90 mg 
four times per day were administered. Repeat an- 
giography was performed at day 7- 10. 
PTCA Procedure. One hundred patients under- 
went immediate PTCA. Following an additional 
dose of heparin 5000 U, a steerable balloon cath- 
eter system was used. The balloon was inflated 
serially until there was at least a 50% reduction in 
the initial infarct vessel stenosis. The angiographic 
exclusion criteria for PTCA included: (1) left main 
coronary stenosis >50%; (2) “left main equiva- 
lency”: 270% stenosis in both the proximal left 
anterior descending and proximal left circumflex 
coronary arteries; (3) diffuse, multivessel disease 
not amenable to PTCA; (4) an unidentifiable in- 
farct vessel; and ( 5 )  an infarct vessel stenosis 
4 0 % .  
Assessment of Left Ventricular Function and 
Coronary Arteriography. Left ventricular function 
was determined from contrast ventriculography 
obtained acutely and on repeat study at day  7-10. 
The end-diastolic and end-systolic endocardia1 
contours of the right anterior oblique ventriculo- 
gram were traced manually and digitized into a 
digital radiographic computer (ADAC Laborato- 
ries, DPS 4 1OOC) for processing. All studies were 
blinded to patient identity, time of study, type of 
intervention, and coronary anatomy. Technically 
inadequate ventriculograms due either to poor 
opacification of the chamber or an inability to gen- 
erate at least one sinus beat were not included in 
the analysis. Left ventricular ejection fraction 
(LVEF) and infarct zone regional wall motion 
(RWM) were determined from the area length18 
and center-line chord [expressed in units of stan- 
dard deviation (SD) per chord]’’ methods, respec- 
tively. 
Percent diameter stenosis of the infarct-related 
artery at day 7-10 was determined by a blinded 
observer using caliper measurement. The projec- 
tion in which the lesion appeared the most severe 
was selected for analysis. In addition, patency was 
assessed using TIMI flow grade.20 For the purpose 
of this study, occlusion was defined as TIMI flow 
0/1 and patency as TIMI flow 2/3. 
Statistical Analysis. All results were given as 
mean k standard deviation. Univariate analysis 
was performed with Student’s t-test, paired t-test, 
Chi-square test, analysis of variance, analysis of 
covariance, and pairwise multiple comparisons. 
Linear regression analysis was used to determine 
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the effect of residual stenosis on left ventricular 
function. The joint predictive importance of vari- 
ables for left ventricular functional improvement 
was examined using stepwise multiple regression 
in conjunction with all possible subsets (APS) re- 
gression. A probability of less than 0.05 was con- 
sidered significant. 
Results 
Of the 129 patients, 82% were males. The mean 
age was 54 10 years. Forty-one percent had an 
anterior myocardial infarction. Thirteen percent 
had a history of prior myocardial infarction. Forty 
percent had multivessel disease (270% stenosis in 
a noninfarct vessel) on coronary angiography. The 
time to treatment was 3.6 k 1.6 hours. 
In the overall group, there was a 2 k 9% increase 
in LVEF ( 5  1 k 11 to 53st 12%, p < 0.02) and a 0.7 
k 1.2 SD/chord increase in RWM (-2.7 +- 1.0 to 
-2.0 t 1.4 SD/chord, p < 0.000 1 ) between day 1 
and day 7-10. 
Determinants of Myocardial Recovery (Univar- 
iate Analysis) 
Patency. The effect of patency on left ventricu- 
lar function is shown in Table I. There was no 
difference between patients with a patent infarct- 
related artery and those with an occluded artery in 
LVEF or RWM at acute catheterization (day 1). 
At repeat catheterization (day 7- lo), patients who 
demonstrated sustained patency of the infarct-re- 
lated artery manifested greater improvement in 
LVEF and RWM than patients who had an oc- 
cluded artery. 
Residual Stenosis at Day 7-10. Subset analysis 
revealed 96 patients with a residual stenosis < 70% 
at day 7-10, 15 patients 70%-99%, and 18 patients 
100% (Table 11). Patients with a residual stenosis 
< 70% had more significant improvement in 
LVEF and RWM than patients with an occluded 
artery. There was no difference in left ventricular 
function between patients with a 70%-99% resid- 
ual stenosis and patients with an occluded artery. 
For patients who manifested sustained patency 
of the infarct-related artery at day 7-10, regression 
analysis demonstrated an inverse association be- 
tween residual stenosis and the change (A) in 
RWM (p < 0.04) between day 1 and day 7-10 and 
a trend towards significance in ALVEF (p < 0.06), 
Time to Treatment. There were 48 patients 
treated < 3 hours and 81 patients 2 3 hours after 
symptom onset (Table 111). Patients treated < 3 
hours had more significant improvement in RWM 
than patients treated 2 3 hours. There was no dif- 
ference in LVEF between the two groups. 
Type of Therapy. The effect of type of therapy 
on left ventricular function is depicted in Table IV. 
Patients treated with combined thrombolytic ther- 
apy and PTCA demonstrated a more significant 
ARWM than patients treated with thrombolytic 
therapy alone. Patients undergoing PTCA alone 
demonstrated a trend towards a more significant 
ARWM when compared to the thrombolytic ther- 
apy alone group. The PTCA alone and the com- 
bined thrombolytic therapy and PTCA groups 
were observed to have greater numbers of patients 
with aresidual stenosis t 7 0 %  than the thrombolytic 
therapy alone group. Patency at day 7- 10 was sim- 
ilar in the three groups. Initiation of treatment was 
significantly longer in the PTCA alone group than 
in the other two groups. 
Initial Global EF. One hundred nine patients 
were observed to have a LVEF 2 40% (mean 54 
f 9%) and 20 patients an LVEF < 40% (mean 34 
f 4%) at day 1. The latter group demonstrated a 
Table I. Effect of Patency on Left Ventricular Function 
Patency at Acute (Day 1 )  Catheterization 
Patent Occluded 
(n = 69) (n = 59) p value 
EF (%) 
Day 1 52 f 12 50 f 10 NS 
Day 7- I0 54 f 12 52 f 12 NS 
Change 2 & 9  2 + 8  NS 
RWM (SD/chord) 
Day I -2.6 f 1.1 -2.9k 1.0 NS 
Day 7-10 -2.Of 1.4 -2.2f 1.3 NS 
Change 0.6 * 1.2 0.7+ 1.2 NS 
Patency at Repeat (Day 7-10) Catheterization 
Patent Occluded 
(n = 111) (n = 18) pvalue 
EF (%) 
Day I 51 * I 1  52 k 8 NS 
Day 7-10 54 f 12 47 -t 11 10.04 
Change 3 k 8  - 5 f 9  0.0002 
RWM (SD/chord) 
Day I -2.7 -t 1.1 -2.9 f 0.7 NS 
Day 7-10 -1.9 k 1.4 -2.8 k 0.9 0.008 
Change 0.8k 1.2 0.1 f 1.0 <0.02 
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Table 11. Effect of Residual Stenosis (Day 7-10) on Left Ventricular Function 
I I1 111 
<70% 70-998 100% 
(n = 96) ( n =  15) (n = 18) p value" 
EF (W) 
Day 1 
Day 7- 1 O* 
Change** 
Day I 
Day 7- 10' 
Change** 
RWM (SD/chord) 
Time to treatment (hrs) 
*I vs I1 
I vs 111 
I1 vs 111 
'I vs I1 
I vs 111 
I1 vs I11 
51 f 12 
54 & 12 
3 + 8  
50 f l l  
51 f 10 
1 + 9  
-2.8 i 1.1 -2.4 f 0.9 
-1.9 f 1.4 -2.2 f 1.1 
0.9 f 1.2 0.2 f 0.8 
3.6 f 1.7 3.5 f 1.2 
Pairwise multiple comparisons: Groups I, 11, I11 
p = N S  
p < 0.1 
p = N S  
p = N S  
p < 0.05 
p = NS 
**I vs I1 
I vs I11 
I1 vs 111 
**I vs I1 
I vs I11 
I1 vs 111 
52 +. 8 
47 + 11 
-5 f 9 
-2.9 f 0.2 
-2.8 + 0.9 
0.1 f 1.0 








p = N S  
p < 0.01 
p = NS 
p = N S  
p < 0.05 
p =NS 
Analysis of variance: Groups I, 11,111. 
more significant ALVEF than the former (7 f 8 vs 
1 k 8%, p < 0.007). 
Infarct Location. Fifty-three patients had an an- 
terior and 76 patients an inferior myocardial in- 
farction (Table V). A significant improvement in 
LVEF was noted only in patients with an anterior 
infarction. Both groups manifested comparable 
RWM recovery. 
Clinical Characteristics. Age, sex, history of 
prior myocardial infarction, multivessel coronary 
artery disease, and presence of angiographically 
visible collaterals had no effect on left ventricular 
function (Table VI). 
Table 111. Effect of Time to Treatment on Left 
Ventricular Function 
<3 hours 23  hours 




Day 1 50 + 11 52 k I 1  
Day 7- 10 53 f 13 53 f 12 
Change 3 * 12 1 f 12 
Day I -2.7 f 1.1 -2.8 f 1.0 
Day 7-10 -1.7 + 1.5 -2.3 rt 1.3 
RWM (SD/chord) 







Determinants of Myocardial Recovery (Step- 
wise Multiple Regression). Stepwise multiple re- 
gression demonstrated that residual stenosis at day 
7-10 (p = O.OOOl), time to treatment (p < 0.04), 
and initial global EF < 40% (p < 0.01) were the 
significant joint predictors of global and regional 
functional improvement. 
Discussion 
The results of this study suggest that the efficacy 
of emergent coronary intervention in promoting 
left ventricular functional recovery in patients 
with acute myocardial infarction is dependent 
upon infarct vessel patency and residual stenosis at 
day 7-10, time and type oftreatment, the degree of 
initial global impairment, and infarct location. 
Stepwise multiple regression, hrthermore, identi- 
fied residual stenosis, time to treatment, and initial 
global impairment as the key joint predictors of 
myocardial functional improvement. 
The role of residual stenosis in left ventricular 
functional recovery has previously been described 
by Sheehan et Our study in contrast assessed 
residual stenosis at day 7-10, not acutely. Deter- 
mination of residual stenosis at a later date may be 
more accurate since the severity of the lesion fol- 
lowing successful reperfusion tends to be overesti- 
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Table IV. Effect of Type of Treatment on Left Ventricular Function 
I11 
I1 Thrombolytic 
I Thrombolytic Therapy 
PTCA Therapy + PTCA 









Residual stenosis at day 




Time to treatment (hrs)? 
*I vs I1 
I vs I11 
11 vs 111 
**I vs 11 
I vs 111 
I1 vs 111 
51 + 10 51 i 12 
54 f 10 51 f 12 
3 + 8  0 + 9  
-2.8 f 0.8 -2.5 * 1.2 
-2.0 f 1.2 -2.3 + 1.2 







5.1 2 2.3 3.4 * 1.1 
Pairwise multiple comparisons: Groups I, 11,111 
p = 0.01 
p = NS 
p < 0.05 
p < 0.05 
p = NS 
p < 0.05 
*I vs I1 
I vs 111 
I1 vs 111 
TI vs I1 
I vs 111 
I1 vs 111 
51 f 12 
53 * 14 
2 f 9  
-2.8 k 1 . 1  
-2.0 i 1.6 















p < 0.05 
p = NS 
p < 0.05 
p < 0.01 
p i 0.01 
p = NS 
" Analysis of variance: Groups I, 11, 111. 
mated at acute catheterization given the presence 
of residual thrombus.22 The effect of residual ste- 
nosis on left ventricular function might be ex- 
plained by the fact that (1) infarct size directly 
Table V. Effect of Infarct Location on Left 
Ventricular Function 
EF% 
Day 1 Day 7-10 Change p value 
Anterior MI 
Inferior MI 
(n =53)  46 f 12 49 k 12 3 k 10 <0.04 




(n = 53) -2.7f 1.2 -2.1 f 1.3 0.6 f 1.3 NS 
(n = 76) -2.7 f 0.9 -2.1 i 1.4 0.6 k 1.2 NS 
correlates with the severity of the residual steno- 
sis23 and (2) following successful thrombolysis, pa- 
tients often have a high grade residual stenosis 
which predisposes them to recurrent ischemia, 
r e i n f a r ~ t i o n , ~ ~ - ~ ~  and presumably poorer left ven- 
tricular function. 
Patients who were treated with combined 
thrombolytic therapy and immediate PTCA or im- 
mediate PTCA alone demonstrated significant im- 
provement in regional function when compared to 
patients treated with thrombolytic therapy alone. 
The fact that the PTCA-treated groups manifested 
less residual stenosis at day 7-10 might explain 
this difference. The effect of immediate PTCA on 
myocardial recovery has been confirmed by pre- 
vious studies. O'Neill and colleagues found that 
PTCA, given its ability to more effectively reduce 
residual stenosis, led to greater functional recovery 
than intracoronary streptokinase." Topol et al. 
demonstrated more significant regional recovery 
in patients treated with combined rt-PA and 
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Table VI. Effect of Clinical and Angiographic Variables on Left Ventricular Function 
Age (years) 
<60 (n = 85) 
260 (n = 44) 
p value 
male (n = 106) 
female (n = 23) 
p value 
Prior infarction 
yes(n = 17) 
no(n  = 112) 
p value 
Multivessel disease 
yes (n = 50) 
no (n = 79) 
p value 
Collaterals 
yes (n = 42) 
no (n = 87) 
I, value 
Sex 
EF (%) RWM (SD/chord) 
Day 1 Day 7- I0 Change Day 1 Day 7-10 Change 
5 2 *  1 1  5 4 f  12 2 *  8 -2.6 * 1 . 1  -2.0 f 1.4 0.6 f 1.2 
49 f 10 52 + 12 3 f  9 -2.9 f 0.9 -2.1 & 13 0.8 & 1.2 
NS NS NS NS NS NS 
51 f 1 1  53 * 12 2 f  8 -2.7 f 0.9 -2.0 f 1.3 0.7 f 1.2 
5 3 f  12 5 4 +  13 I f  9 -2.7 f 1.5 -2.2 f 16 0.5 2 1.2 
NS NS NS NS NS NS 
5 2 f  1 1  54? 12 2 f  9 -2.6 f 1 . 1  -2.0 f 1.4 0.6 f 1.2 
4 8 +  1 1  4 9 +  12 1 +  7 -3.1 f 0.6 -2.4 f 1.2 0.7 f 1.2 
NS NS NS NS NS NS 
52 f 12 53 f 13 I f  8 -2.7 f 1 . 1  -2.1 f 1.3 0.6 * 1.2 
50 + 10 53 f 1 1  3 +  10 -2.8 f 10 -2.0 f 1.5 0.8 & 1.2 
NS NS NS NS NS NS 
5 2 f  1 1  53  * 12 I f  9 -2.7 f 1.0 -2.0 f 1.4 0.7 f 1 . 1  
52 f 10 5 4 f  12 2rt 7 -2.9 f 0.7 -2.4 f 1.3 0.5 f 1 . 1  
NS NS NS NS NS NS 
PTCA than those patients treated with rt-PA 
alone.27 The former group had less residual steno- 
sis and a decreased incidence of recurrent ischemic 
events. The results of our study, nevertheless, 
differ with those of the TAM1 Trial2* and the Euro- 
pean Cooperative Study9 where immediate PTCA 
was found not to improve LVEF following throm- 
bolytic therapy. Residual stenosis, however, was 
not assessed in these trials. Of interest, the PTCA 
alone group, despite being treated at a later time 
interval, demonstrated more significant improve- 
ment in regional function than the thrombolytic 
therapy alone group. This finding might be due to 
the ability of PTCA to more definitively reduce the 
underlying atherosclerotic lesion. The degree of re- 
sidual stenosis may therefore be a more powerful 
predictor of left ventricular functional recovery 
than time to treatment. 
Sustained patency at day 7-10 appeared to be a 
more important predictor of myocardial recovery 
than initial patency. Loss of patency at day 7-10, 
moreover, was associated with a decline in global 
function. 
Left ventricular function was influenced by time 
to treatment. Patients treated < 3 hours after 
symptom onset demonstrated more significant im- 
provement in RWM than patients treated 2 3 
hours. There was no difference, however, in LVEF 
between the two groups. Several clinical studies 
have reported that the critical window for global 
recovery by coronary intervention occurs within 2 
h o ~ r s . ~ ’ , ~ ~  Koren et al., moreover, found that 
streptokinase administered later than 1.5 hours 
after symptom onset resulted in little gain in 
LVEF.32 The lack of global improvement in our 
study may therefore be attributable to the fact that 
few patients were treated within 2 hours. 
Previous reports have suggested that the magni- 
tude of myocardial recovery following thrombo- 
lytic therapy appears dependent upon the degree 
of initial impairment or infarct location.3s36 Pa- 
tients with severely depressed left ventricular func- 
tion derive more benefit from reperfusion owing to 
the greater potential for improvement. In our 
study, patients with an initial LVEF < 40% and 
those with an anterior myocardial infarction man- 
ifested the greatest recovery in global function. In 
contrast, patients with well-preserved baseline 
function demonstrated minimal improvement. 
The importance of angiographic visible collat- 
erals remains unclear. Although several studies 
have noted functional improvement with collat- 
eral pre~ence,~’*~~ we found no such association. In 
addition, sex, age, presence of multivessel disease, 
and history of prior myocardial infarction had no 
effect on left ventricular function. 
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Limitations. Because LVEF is a measure of the 
ischemically impaired infarct zone and the hyper- 
dynamic noninfarct zone, it may be an insensitive 
means of assessing myocardial preservation. With 
regression of the compensatory hyperkinesia 
which often occurs before infarct zone recovery,39 
LVEF in the early postinfarct period may remain 
unchanged or even decrease. Furthermore, maxi- 
mum improvement in global and regional func- 
tion may not be seen for 6 monthsm Our study 
in evaluating ventricular function at day 7-10 
may therefore have underestimated the degree of 
recovery. 
Conclusions and Future Directions 
Early restoration of coronary blood flow and 
definitive recanalization to reduce the underlying 
residual stenosis appears critical in promoting 
myocardial recovery. The efficacy of thrombolytic 
therapy in preserving left ventricular function may 
be limited by an inability to re-establish antero- 
grade flow in a significant proportion of pa- 
t i e n t ~ ~ , ~ ' ~ ~  and by the persistence of a high grade 
residual stenosis. In contrast, PTCA, despite ad- 
dressing the underlying atherosclerotic lesion, is an 
involved procedure limited to institutions with a 
cardiac catheterization laboratory and skilled per- 
sonnel. Combined thrombolytic therapy and 
PTCA may therefore be a more practical alterna- 
tive. Intravenous thrombolytic therapy can be ini- 
tiated rapidly and safely in most health care facili- 
ties and FTCA subsequently performed in an ap- 
propriate hospital setting. The optimal timing for 
PTCA remains unclear and is the focus of several 
ongoing randomized trials. The results of this 
study suggest that an aggressive approach to acute 
myocardial infarction be aimed at patients who 
have a high grade residual stenosis, present early 
after symptom onset, and manifest extensive 
myocardial insult. 
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